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Porphyrin metabolismThe nuclear receptor, REV-ERBa, has a key role in circadian rhythms and requires heme as its ligand.
The present study determined whether the heme precursor, 5-aminolevulinic acid (ALA), affects
REV-ERBa and its target genes. When exposed to ALA, the human lung diploid cell line, WI-38, exhib-
ited activation of REV-ERBa and repression of the transcription of REV-ERBa target genes, including
BMAL1, an essential component of the circadian oscillator. Moreover, co-incubation of sodium fer-
rous citrate (SFC) and ALA also activated REV-ERBa and repressed the transcription of REV-ERBa tar-
get genes. These results indicate that ALA regulates human circadian rhythms via REV-ERBa.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Humans have circadian rhythms that allow them to adapt to
environmental change caused by the earth’s rotational period [1–
3]. The suprachiasmatic nucleus in the hypothalamus is known
to control the central clock in mammalian cells. Many tissues have
circadian rhythms referred to as peripheral clocks in addition to a
central clock [4]. Circadian rhythm is controlled by feedback loops
consisting of transcription and translation of clock proteins and is
mainly regulated by loops consisting of the heterodimeric protein
complex of BMAL1/CLOCK, BMAL1/NPAS2, and PER/CRY. The com-
plex of BMAL1/CLOCK and BMAL1/NPAS2 activate transcription of
clock genes, including PER and CRY, by binding E-box [5,6]. These
transcriptional products form the complex and suppress the activ-
ities of BMAL1/CLOCK and BMAL1/NPAS2 [2,4]. REV-ERBa and
REV-ERBb, typical nuclear receptors, strongly modulate circadian
rhythms by binding to the ROR region of BMAL1 or CLOCK and sup-
presses the expression of these genes [7]. Heme was reported to bea ligand of REV-ERBa and REV-ERBb and found to be fundamen-
tally important for their activities [8,9].
5-Aminolevulinic acid (ALA) is widely distributed in both plants
and animals and is the common precursor of heme [10]. ALA admin-
istration induces cancer-speciﬁc accumulation of ﬂuorescent
protoporphyrin IX (PpIX) [11]. Therefore, ﬂuorescence diagnosis,
also termed photodynamic diagnosis, is based on the different
ALA-induced ﬂuorescent signatures of normal and cancer tissues
[12]. In contrast, in a normal tissue, the iron ion is inserted into PpIX
to form heme in the mitochondria and incorporated into hemopro-
teins. Our previous study showed that the administration of ALA
increased cytochrome c oxidase activity inmice [13]. These ﬁndings
strongly suggest that the administration of ALA leads to the
accumulation of intracellular heme. The present study tested the
possible impact of ALA on the endogenous activities of REV-ERBa
in vitro to determine whether this compound inﬂuences circadian
rhythms in human cells. This study demonstrates the potential of
ALA as an endogenous compound that affects circadian rhythms.
2. Materials and methods
2.1. Biochemicals
ALA hydrochloride and sodium ferrous citrate (SFC) were pur-
chased from Cosmo Oil Co., Ltd. (Tokyo, Japan). Dulbecco’s modi-
ﬁed Eagle’s Medium (DMEM) and protease inhibitor cocktail and
348 K. Yamashita et al. / FEBS Open Bio 4 (2014) 347–352antibiotic–antimycotic solution were obtained from Nacalai Tes-
que (Kyoto, Japan). Fetal bovine serum (FBS) and horse serum were
purchased from Invitrogen (Carlsbad, CA, USA). All other chemicals
used were of analytical grade.
2.2. Cell culture
Human lung diploid cells (WI-38) were purchased from RIKEN
Cell Bank (Tsukuba, Japan). The cells were maintained under 5%
CO2 gas at 37 C in DMEM supplemented with 10% (v/v) fetal bo-
vine serum and 1% (v/v) antibiotic–antimycotic solution.
2.3. HPLC analysis of PpIX and heme
Cells (1  106 cells) were incubated with 1 mM ALA and 0.5 mM
SFC in DMEM under 5% CO2 gas at 37 C in the dark each time. Cells
were rinsed with 1 ml of phosphate-buffered saline (PBS) and then
treated with 300 l1 of 0.1 M NaOH. An aliquot (10 ll) of the
NaOH-treated cell sample was withdrawn and used for protein
concentration assay (Quick Start™ Bradford protein assay, Bio-
Rad Laboratories, Inc., CA, USA), whereas the remaining cellular
proteins were denatured by adding 3-fold volumes of solvent A
[l M ammonium acetate, 12.5% acetonitrile (v/v)]: solvent B
[50 mM ammonium acetate, 80% acetonitrile (v/v)] (1:9 v/v) solu-
tion to the NaOH-treated cell sample. The prepared sample was
centrifuged at 12,000 rpm for 10 min at 4 C and subjected to
high-performance liquid chromatography (HPLC) analysis per-
formed as previously described with some modiﬁcations [14,15].
In brief, protoporphyrin IX (PpIX) and heme were separated using
the HPLC system (Prominence, Shimadzu, Kyoto, Japan) equipped
with a reversed-phase C18 column (CAPCELL PAK, C18, SG300,
5 lm, 4.6 mm  250 mm, Shiseido, Tokyo, Japan). Elution was
started with 10% solvent A and 90% solvent B for 7 min. The elution
ﬂow throughout was kept constant at a rate of 2.0 ml/min. PpIX
and heme were continuously detected using a spectrophotometerR
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Fig. 1. Intracellular PpIX (A) and heme (B) accumulation and relative expression levels
1 mM ALA and 0.5 mM SFC (white) or ALA alone (gray). PpIX and heme accumulation
determined by real-time PCR analysis and Western blot analysis respectively. Results reat 404 nm. The concentration of the samples was estimated using
calibration curves of reference standards.
2.4. Quantitative PCR
A High Pure RNA Isolation Kit (Roche Ltd., Mannheim, Germany)
was used to extract total RNAs from the cells according to the man-
ufacturer’s protocol [16,17]. One microgram of total RNAs was re-
verse-transcripted to produce ﬁrst strand cDNA using the
PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa, Shiga, Japan)
according to the manufacturer’s protocol [16,17]. The Thermal Cy-
cler Dice Real Time System (TaKaRa, Shiga, Japan) was used for a 2-
step reverse transcription polymerase chain reaction (PCR). The
mRNA transcripts were quantiﬁed by SYBR Premix ExTaq (TaKaRa,
Shiga, Japan). HO-1 speciﬁc primers 50-GCTCAAAAAGATTGCCCA-
GAA-30 and 50-TCACATGGCATAAAGCCCTACA-30 were used. The
other primers were purchased from TaKaRa. The ampliﬁcation con-
ditions included 30 s at 95 C, a run of 45 cycles at 95 C for 5 s, and
60 C for 60 s followed by dissociation for 15 s at 95 C and 30 s at
60 C and then 15 s at 95 C on the Thermal Cycler Dice Real Time
System. The Thermal Cycler Dice Real Time System analysis soft-
ware (TaKaRa, Shiga, Japan) was used to analyze the data. The Ct
values (cycle threshold) were calculated by the crossing-point
method, and the relative quantities of target mRNA expression lev-
els were measured by the comparison of standard curve. The re-
sults for each sample were normalized to ACTB, the housekeeping
gene.
2.5. Western blot analysis
Western blot analysis was performed as previously described
with some modiﬁcations [18]. Cells were lysed in whole-cell lysis
buffer A [50 mM Tris–HCl (pH 7.4), 1 mM DTT, 1% (v/v) Triton X-
100, and protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan)].
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of HO-1 mRNA (C) and HO-1 protein (D) in WI-38 cells. Cells were incubated with
were determined by HPLC analysis. Expressions of HO-1 mRNA and proteins were
present the mean ± SD.
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Fig. 2. Heme accumulation (A), HO-1 protein level (B) and RER-ERBa protein level
(C) in nuclear fraction from WI-38 cells. REV-ERBa protein level in cytoplasmic (C)
and nuclear (N) fractions were determined. Cells were incubated with 1 mM ALA
and 0.5 mM SFC or ALA alone for 2 h. Results represent the mean ± SD. Statistical
signiﬁcance of difference is indicated by ⁄p < 0.01 as compared between paired
groups. Statistical signiﬁcance was calculated using Student’s t-test.
K. Yamashita et al. / FEBS Open Bio 4 (2014) 347–352 349(SDS–PAGE) was used to separate 20 lg of lysates, which were
then transferred to polyvinylidene diﬂuoride membranes. The fol-
lowing primary antibodies were used to probe the blots: anti-
ALAS1 (Abcam, Cambridge, UK, ab54758), anti-BMAL1 (Abcam,
Cambridge, UK, ab3350, [19]), anti-HO-1 (Abcam, Cambridge, UK,
ab13248, [20]), anti-NR1D1 (Abcam, Cambridge, UK, ab56754,
[21]), anti-ACTIN (MP Biomedicals, Irvine, CA, USA, 69100), and
anti-HDAC3 (Cell Signaling Technology, Beverly, MA, USA, 3949).
For the second antibody, we used anti-mouse IgG HRP-conjugated
antibody (Cell Signaling Technology, Beverly, MA, USA) and anti-
rabbit IgG HRP conjugates (Santa Cruz Biotechnology) at 1:3000
dilution.
2.6. Nuclear extraction
An EpiQuik Nuclear Extraction Kit II (Epigentek Group Inc.,
Brooklyn, NY, USA) was used to isolate nuclear extracts according
to the manufacturer’s protocol. HPLC and Western blot analysis
were used to determine heme accumulation and protein expres-
sion levels, respectively.
2.7. Serum stimulation
To synchronize circadian rhythms, serum stimulations were
performed [22]. Cells (5  106 cells/well) were pre-incubated with
or without 1 mM ALA and 0.5 mM SFC in DMEM supplemented
with 10% FBS for 4 h. Then cells were collected as zero-point and
started the collection as below. In the ﬁrst 2 h, cells were stimu-
lated by changing the medium to serum-rich (50% (v/v) horse ser-
um) DMEM to synchronize circadian rhythms with or without
1 mM ALA and 0.5 mM SFC; this medium was then replaced with
serum-free DMEM with or without 1 mM ALA and 0.5 mM SFC
after 2 h. In ALA and SFC addition group, 1 mM ALA and 0.5 mM
SFC were re-added after 24 h. At the indicated times after serum
stimulation, the cells were washed twice with 1 ml of PBS. The cells
were collected for RNA extraction at the indicated time points.
3. Results
In the present study, to accumulate intracellular heme, ALA was
administered. Because heme is formed by the insertion of the iron
ions into PpIX converted from ALA, the effect of administration of
SFC (used as an iron ion source) was investigated. Fig. 1A shows
intracellular PpIX accumulation after incubation with ALA and
SFC or ALA alone. WI-38 cells were used in this study. Intracellular
PpIX accumulation was observed by ALA incubation; however,
PpIX accumulations were decreased by ALA/SFC co-incubation.
This decreased PpIX was converted into heme by co-incubation
of ALA and SFC. The intracellular heme level was measured using
HPLC (Fig. 1B). Heme accumulation was slightly observed 2 h after
ALA/SFC co-incubation; however, signiﬁcant changes were not ob-
served. Heme is known to be degraded by HO-1 immediately;
therefore, HO-1 levels were investigated after ALA and SFC incuba-
tion. Fig. 1C shows mRNA expression levels of HO-1, and Fig. 1D
shows protein expression levels of HO-1 measured using Western
blotting after ALA and SFC incubation showing HO-1 levels were
increased in ALA incubation and ALA/SFC co-incubation. These re-
sults indicate that heme was accumulated and degraded by HO-1.
Furthermore, HO-1 level was higher in ALA and SFC co-incubation
than in ALA incubation only, which indicated that heme accumula-
tion in ALA and SFC co-incubation were higher than that in ALA
incubation.
REV-ERBa functions after binding to heme as a ligand in the nu-
cleus. Therefore, HPLC was used to determine intranuclear heme.
Fig. 2A shows intranuclear heme concentrations after ALAincubation for 2 h with and without SFC. Intranuclear heme after
ALA incubation was signiﬁcantly increased. Intranuclear heme
after ALA/SFC co-incubation was higher than that of the control
but lower than that after only ALA incubation. These results indi-
cate that excess heme was degraded by HO-1. In Fig. 2B, HO-1 pro-
tein expression levels in nuclear fractions showing apparent
inductions of HO-1 are observed. Furthermore, protein expression
levels of REV-ERBa in the nucleus were increased by ALA incuba-
tion and ALA/SFC co-incubation (Fig. 2C). In Fig. 2C, band intensi-
ties were quantiﬁed resulting ALA incubation resulted 1.1 times
higher than without ALA incubation (control) and ALA/SFC co-incu-
bation resulted 1.6 times higher than control. These results
strongly indicate that ALA incubation and ALA/SFC co-incubation
leads to heme accumulation in the nucleus and induces REV-ERBa.
REV-ERBa is known to regulate the expression of target genes,
such as PGC-1a, ALAS1, and BMAL1. The mRNA expression levels
of PGC-1a (Fig. 3A), ALAS1 (Fig. 3B), and BMAL1 (Fig. 3C) were mea-
sured using real-time PCR after ALA incubation and ALA/SFC co-
incubation. The mRNA expression levels of all 3 genes were sup-
pressed within 1 h. As shown in Fig. 2, the intranuclear heme level
increases in 2 h, and heme is degraded by HO-1. This result is in
good agreement with the results that target genes of REV-ERBa
were suppressed within 1 h. Moreover, the protein expression lev-
els of ALAS1 and BMAL1 were suppressed (Fig. 3D), which showed
that REV-ERBa repressed the transcription of target genes.
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Fig. 3. Relative mRNA expression levels of PGC-1a (A), ALAS1 (B), BMAL1 (C) and protein expression levels (D) in WI-38 cells. Cells were incubated with 1 mM ALA and 0.5 mM
SFC (white) or ALA alone (gray). Results represent the mean ± SD.
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Fig. 4. Relative mRNA expression levels of REV-ERBa (A), and BMAL1 (B) after 50% serum shock. Cells were incubated with 1 mM ALA and 0.5 mM SFC (white) or ALA alone
(gray). Results represent the mean ± SD.
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Fig. 5. Schematic illustration of the heme synthesis and the activation of REV-ERBa in this study.
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tion activated the expression of REV-ERBa and suppressed its tar-
get genes, including clock genes. It is well known that serum
stimulations cause synchronizing circadian rhythms and that the
amplitude and cycle of circadian rhythms could be detected.
Fig. 4 shows the effect of ALA incubation and ALA/SFC co-incuba-
tion on circadian rhythms after serum stimulations. The expression
levels of REV-ERBa were increased by ALA incubation and ALA/SFC
co-incubation (Fig. 4A). This result is in good agreement with that
of Fig. 2C, which shows that REV-ERBa protein level was increased.
Furthermore, the expression of BMAL1, a typical target gene of
REV-ERBa, was suppressed by ALA/SFC co-incubation (Fig. 4B). Be-
cause these genes strongly affect circadian rhythms, ALA and ALA/
SFC incubation could affect circadian rhythms.
4. Discussion
Since the mouse Clock gene was discovered [23], many studies
on circadian rhythms have been performed. Recent studies have
shown that abnormal circadian rhythms increase the risk for dia-
betes, bipolar disorder, cancer, and coronary events [24–27]. These
results strongly suggest that the shift to normal circadian rhythms
from abnormal circadian rhythms is quite important. Kaasik et al.
showed that addition of hemin, the Fe(III) form of heme, affected
circadian rhythms [28]. However, the addition of hemin leads to
increased free-heme and cytotoxicity [29]. From the above results,
the administration of heme or hemin to humans is quite difﬁcult.
ALA is used in various ﬁelds, especially cancer diagnosis (photo-
dynamic diagnosis) and cancer therapy (photodynamic therapy)
[10]. There are no reports of toxic side effects caused by ALA
administration. It is well known that ALA is converted into heme
and that heme has an important role in the activation of REV-ERBa.
Therefore, in the present study, the effects of ALA on circadian
rhythms via REV-ERBa were investigated. ALA incubation led to
the activation of heme biosynthesis and suppression of REV-ERBa
target genes (Fig. 5). Moreover, these effects were enhanced by
ALA/SFC co-incubation, and ALA/SFC co-incubation affected the
oscillation and phase of core clock genes. These phenomena were
supported by increased heme level in the nucleus. To our knowl-
edge, this is the ﬁrst attempt to regulate circadian rhythms using
ALA.
Because the target gene of REV-ERBa is known to cause several
diseases, drug design strategies that modulate REV-ERBa activity
are expanding [30–32]. Laura et al. showed that SR9009a and
SR9011 acted as strong agonists and modulated several clock genes
[32]. Because ALA also modulated REV-ERBa; therefore, ALA could
be a new candidate of REV-ERBa modulator that regulates severaldiseases. However, further research is required to examine the ac-
tual contribution of ALA in vivo using experimental animal models.
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